• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Exopharm

Exopharm

  • Home
  • Partnering
  • Science
  • Resources
    • ASX Announcements
    • News & Articles
    • Investor Information
  • About Us
    • Our Values
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Contact

News & Articles

  • All
  • News
  • Papers

November 23, 2022 By Exopharm Ltd

Sartorius BIA Separations and Exopharm sign joint research agreement to develop integrated technology for large-scale exosome production

  Sartorius BIA Separations and Exopharm sign joint research agreement to develop integrated technology for large-scale exosome production Partnership will address technical challenges of large-scale, high-efficiency purification of therapeutic exosomes for non-viral drug delivery Programme combines novel technologies and expertise – LEAP exosome purification technology from Exopharm and BIA’s CIM monoliths   Melbourne, Australia and […]

Filed Under: News

November 23, 2022 By Exopharm Ltd

‘Limitless future of RNA therapeutics’ – and what that means for exosomes and Exopharm (ASX:EX1)

Link to PDF of release Introduction: ‘The time for exosomes as an essential part of modern medicines is with us’ explains Dr Ian Dixon, founder and CEO of Exopharm. Advances made by Exopharm with its exosome technologies coincides with heightened interest in mRNA therapeutics [1]. Drug-delivery is the main hurdle holding back many potential mRNA […]

Filed Under: News

October 10, 2022 By Exopharm Ltd

Momentum Building with Products – Exopharm (ASX:EX1)

Key Highlights Exopharm has a new Investor Presentation available to shareholders and investors on our website 2 lead Genetic Medicine (GM) programs have been selected for our in-house product development investment These products have been selected considering potential future commercial value and as a way to showcase exosomes as a non-viral nanoparticle ‘chassis’ to overcome drug-delivery problems […]

Filed Under: News

July 11, 2022 By Exopharm Ltd

Exoria helps illuminate the importance of exercise with age.

Scientists at Exopharm have collaborated with Associate Professor Jason Howitt and his research team at Swinburne University of Technology to probe the molecular processes that occur with aging. NAD+ (nicotinamide adenine dinucleotide), an essential metabolite for energy metabolism, declines with age, however extracellular vesicles (EVs) released by the body during exercise can boost NAD+ levels […]

Filed Under: News, Papers

June 23, 2022 By Exopharm Ltd

Expert View: Extracellular Vesicle Engineering: Optimising Nature’s Non-Immunogenic, Drug Delivery Platform

We are pleased to announce that our Expert View article titled “Extracellular Vesicle Engineering: Optimising Nature’s Non-Immunogenic, Drug Delivery Platform” has been published in ONdrugDelivery. You can check out this Expert View article from Exopharm’s Research and Innovation Manager, Dr Anna Cifuentes-Rius  here . Dr Cifuentes-Rius discusses how to take advantage of EV’s capacity to […]

Filed Under: News, Papers

May 26, 2022 By Exopharm Ltd

Exopharm a LEAP ahead of competitors in emerging exosome medicine field

With a rapidly growing global interest in the superpower of exosomes, major pharmaceutical deals and foundational patents, Exopharm is poised to become an essential part of the modern medicine ecosystem.   As the only listed exosome company on the ASX, and one of a small number of exosome companies listed globally, Australian biopharma Exopharm (ASX:EX1) […]

Filed Under: News

February 1, 2022 By Exopharm Ltd

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

  Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial services are designed to seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA Future […]

Filed Under: News

Footer

Resources

  • ASX Announcements
  • Board of Directors
  • News & Articles

Information

  • Contact
  • Partnering
  • Join Our Mailing List
  • Privacy, Terms and Conditions
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Copyright © 2023 · Exopharm · ACN 163 765 991 · info@exopharm.com
Level 17/31 Queen St, Melbourne VIC Australia 3000 · P: +61 (0)3 9111 0026 ·

Web Design by Mallee Blue Media
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT